Other
The company warns of unauthorized individuals posting fraudulent job opportunities under CatenaBio's name and directs users to the official contact form / FTC reporting channels.
SourceUsing protein coupling to build new therapies
Company research
Public company, workplace, funding, and market signals
Overview
UC Berkeley spinout developing its CysTyr® precision-conjugation platform and Multi-Payload Conjugates (MPCs) for next-generation antibody-drug conjugates, initially focused on hard-to-treat solid tumors and with broader applications in oncology, autoimmune disease, and vaccine development.
Primary product
Multi-Payload Conjugates (MPCs) built on the CysTyr® conjugation platform
Founded
2020
Headquarters
Berkeley, California, United States
Team size
10-20
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
Antibody-drug conjugates / protein conjugation therapeutics
Offices
2625 Durant Ave., Berkeley, CA 94720, United States
Business model
platform R&D
biopharma partnerships
grant-supported research
Funding
Stage
seed
Total raised
$8.1M
Latest round
Seed · May 2024
Latest amount
$2.4M
People & investors
Leadership
CEO and Co-founder
Chief Business Officer
Chief Scientific Officer
Director of Technical Operations
Work & culture
Work style
Onsite
Product & market
Differentiators
- —Uses a CysTyr® platform with native amino acids (cysteine and tyrosine) rather than conventional maleimide chemistry
- —Can attach multiple payloads to the same antibody
- —Supports payloads of any size and complexity
- —Offers flexible drug-to-antibody ratio (DAR) control and precise site control
- —C-Y Bond™ is presented as more stable than traditional maleimide bonds, reducing off-target release
Technology
JazzHR
Impact
Google Analytics
Google Domains
Apple iCloud Mail
jQuery
PHP
Font Awesome
html5media
Scale & contact
Estimated monthly visits
2.3K
Signals & risks
Latest news
AACR / Cancer Research · Apr 2025
AACR 2025 abstract describes CatenaBio’s HER2- and TROP2-targeted MPCs, showing superior inhibition and tumor elimination in preclinical models, including CATB-101, with strong tolerability and activity after SG treatment.
CatenaBio / World ADC poster · Nov 2024
World ADC 2024 poster reports MPC superiority versus standard-of-care ADCs, modular library production, and the stability advantages of the C-Y Bond/CysTyr platform.
CatenaBio · Apr 2024
Official company news on its AACR 2024 poster describing a novel conjugation system for multi-payload therapies and preclinical results for MPCs.
CatenaBio · Jan 2024
Company announcement that it was selected to present at the Berkeley Bio Startup Showcase during JPM 2024, highlighting CysTyr and MPC technology and ongoing investor/partner interest.
Business Wire · Aug 2023
Leadership expansion announcement naming Saurabh Johri as CBO and Rick Kendall as CSO; the article also describes Marco Lobba as co-founder and CEO.
Jobs and careers at Catena Biosciences
0 jobs at Catena Biosciences
No open positions
Check back later for new openings